Alnylam Pharmaceuticals (ALNY) PT Raised to $265 at RBC Capital, 'we remain buyers'
Tweet Send to a Friend
RBC Capital analyst Luca Issi raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $265.00 (from $250.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
